Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Signia

Financiado

Cerrado

An innovative drug development and repurposing platform for rapid identification...

An innovative drug development and repurposing platform for rapid identification and validation of antimicrobial therapeutics Pharma industry is facing the challenge of high-cost and time-consuming processes for de novo drug development (€1-2 billion and 10-17 years per marketed drug), also influenced by high failure rates (only 10% of drug candidates ar... ver más

31/05/2023

SIGNIATHERAP

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

SIGNIA THERAPEUTICS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-05-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

SIGNIATHERAP

2.38M€ | Lider

VIPERA IBERICA

490.00K€ | Participante

Proyectos interesantes

IDENTIFICACIÓN DE NUEVOS ANTIBIÓTICOS PARA EL...

Medical Technol...

Data Science

2M€ Cerrado

SIGNIA

Medical Technol...

Data Science

71K€ Cerrado

EDAS HEALTHCARE

Medical Technol...

Data Science

71K€ Cerrado

TAILORED-TREATMENT

Medical Technol...

Data Science

8M€ Cerrado

STriTuVaD

Medical Technol...

Data Science

5M€ Cerrado

AntibioDx

Medical Technol...

Data Science

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 36 meses Fecha Inicio: 2020-05-14
Fecha Fin: 2023-05-31

Líder del proyecto

SIGNIA THERAPEUTICS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pharma industry is facing the challenge of high-cost and time-consuming processes for de novo drug development (€1-2 billion and 10-17 years per marketed drug), also influenced by high failure rates (only 10% of drug candidates are approved for market entry). As a result, an increasing number of firms seek alliances based on repurposing existing drugs for new indications to deliver the needed productivity increases, shifting the focus of R&D to smaller biotech companies. Among all infectious diseases, acute respiratory tract infections are the main source of acute diseases worldwide with over 17.5B deaths per year, notably killing newborns and young children. They are caused by over 200 viruses and handful virus-bacteria coinfections; however, today we only have vaccines and few treatments for Influenza and respiratory syncytial virus. Signia is a French start-up offering a disruptive solution to combat these emerging infections globally; a drug development platform for next-generation antimicrobial treatments, by repurposing ready-marketed drugs and repositioning unsuccessful pharma pipelines candidates. Signia strategy involves a complete paradigm shift, based on targeting the global response of the host cell instead of a specific molecular determinant of the pathogen. Our innovation will not only give rise to better treatments against respiratory infections and significant shortening of response time to widespread outbreaks, but also will enable both a rapid transition of drugs from the pipeline to the market and a rapid return of investment for pharmas. Phase 2 will let us reach the full capability of our platform and the clinical validation of the optimized nebulized Diltiazem, our drug candidates at the most advanced stage of validation as repurposed host-targeted inhibitor of influenza infection. We forecast €31M revenues (with a ROI of 9.72 with a corresponding EBITDA of 70.51% after 5 years in the market) and increase our company´s workforce to 14.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores